400-600-8767
13810794957@163.com
時事通訊
了解蘭貝石最近動態(tài)與行業(yè)資訊
輸入您的電子郵件并完成訂閱
Drugverse
藥宇宙（Drugverse）的創(chuàng)始人郭均相先生
Mr. Guo Junxiang, Founder of Drugverse
|
郭均相先生：1979年12月出生，中國國籍，無境外永久居留權(quán)，云南師范大學(xué)碩士研究生，醫(yī)藥領(lǐng)域超20年工作經(jīng)歷，先后在康恩貝#600572·SH、君業(yè)藥業(yè)（激素CDMO）、DoePharma（CDMO研發(fā)公司）等公司擔(dān)任Director、VP、President。2020年開始出任上市藥企寧波美諾華藥業(yè)#603538·SH、東陽光長江藥業(yè)#01558·HK戰(zhàn)略顧問，因為在收購入股原料藥、醫(yī)藥中間體及CDMO/CRO企業(yè)的市值管理和CXO業(yè)務(wù)（CMO&CDMO為主）、項目Licence in&out上的前瞻性布局，為中國藥企在創(chuàng)新藥/搶仿領(lǐng)域上的產(chǎn)品管線布局指明方向、破局內(nèi)卷上建樹頗豐，2023年初至今，被中國化工企業(yè)管理協(xié)會提名為副會長，并榮獲中國醫(yī)藥行業(yè)著名戰(zhàn)略家美譽。 Mr. Guo Junxiang is a Chinese national born in December 1979, with no permanent residence abroad. He holds a master’s degree from Yunnan Normal University and has over 20 years of experience in the pharmaceutical industry. He has served as a director, vice president, and president in various pharmaceutical companies, such as Zhejiang Conba Pharmaceutical Co., Ltd. (#600572?SH) 、Zhejiang Xianju JUNYE Pharmaceutical Co., Ltd. (steroid CDMO) and DoePharma (CDMO). Since 2020, He has served as a senior business strategy consultant for two Chinese listed pharmaceutical companies: Ningbo Menovo Pharmaceutical Co., Ltd. (#603538?SH) and YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (#01558?HK). Mr. Guo has played a key role in guiding Chinese pharmaceutical companies on their prospective product pipeline planning (both innovative and generic medicines) in terms of stake purchasing API & pharmaceutical intermediate enterprises, managing the market value of CDMO/CRO, developing CXO (mainly CMO&CDMO) business, and conducting In-licensing/Out-licensing. Due to his fruitful achievements in these fields, Mr. Guo was nominated as the vice chairman of the China Chemical Enterprise Management Association in early 2023, and earned the reputation as a renowned strategist in Chinese pharmaceutical industry. |
The CIC2013 China Chemical Drug Industrial Development Summit, co-organized by Drugverse, was successfully held on July 14, 2023. The summit brought together experts, scholars, and industry leaders from the related fields to discuss the latest trends, challenges and opportunities in chemical drug development. The summit also showcased the innovative solutions and products offered by Drugverse, a platform that aims to help pharmaceutical researchers in their drug development process. The summit was a great opportunity for networking, learning, and collaboration among the participants.
2023年7月14日，由Drugverse協(xié)辦的CIC2023中國化學(xué)藥物產(chǎn)業(yè)鏈發(fā)展峰會（CHINA CHEMICAL DRUG INDUSTRIAL DEVELOPMENT CONFERENCE）取得圓滿成功！
中國科學(xué)院院士、中國科學(xué)院上海有機(jī)化學(xué)研究所研究員馬大為參加峰會并為大會開幕致辭，發(fā)表關(guān)于“小分子創(chuàng)新藥物發(fā)展的思考”的主旨演講.
Ma Dawei, an academician of Chinese Academy of Sciences and a researcher at the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences, attended the summit and gave an opening speech. He also delivered a keynote speech on “Thoughts on the Development of Innovative Small Molecule Drugs”, in which he shared his insights and perspectives on the current status and future trends of small molecule drug research.
健艾仕（杭州）生物制藥公司董事長傅新元，進(jìn)行“化學(xué)藥靶點選擇：以JAK- STAT 為例”的精彩分享。
Fu Xinyuan, the Chairman of the Board of GenEros (Hangzhou) Biopharma Ltd., delivered an insightful presentation on “Chemical Drug Target Selection: Using JAK-STAT as a Case Study”.
峰會就“新時代小分子創(chuàng)新藥”設(shè)置圓桌討論環(huán)節(jié)。如何評價一項創(chuàng)新藥研發(fā)項目的商業(yè)潛力和投資價值？小分子創(chuàng)新藥的研發(fā)是否能滿足未來醫(yī)學(xué)需求？如何加強中國創(chuàng)新藥研發(fā)人才培養(yǎng)和引進(jìn)，提高我國在全球創(chuàng)新藥領(lǐng)域的競爭力？小分子創(chuàng)新研發(fā)和新技術(shù)的融合如何推動醫(yī)療創(chuàng)新？圍繞這些問題，郎盛投資集團(tuán)合伙人李佳、維亞生物首席創(chuàng)新官戴晗、燁輝醫(yī)藥科技（上海）有限公司CEO華燁、上海宇道生物技術(shù)有限公司聯(lián)合創(chuàng)始人郁征天，分別作為主持嘉賓，與相關(guān)企業(yè)代表進(jìn)行互動交流。
The summit featured a roundtable discussion session on “Innovative Small Molecule Drugs in the New Era”. The session addressed the following questions: How can one assess the commercial potential and investment value of an innovative drug discovery project? How can the R&D of innovative small molecule drugs meet the future medical needs? How can China enhance its talent training and recruitment in the field of innovative drug R&D and improve its global competitiveness? How can the integration of small molecule innovation R&D and new technologies foster medical technology innovation? These discussion sections were hosted by Li Jia, a partner of Lang Sheng Investment Group Co., Ltd.、 Dai Han, the chief innovation officer of Viva Biotech、Hua Ye, the CEO of BioNova Pharmaceuticals (Shanghai) Ltd., and Yu Zhengtian, the co-founder of Shanghai Nutshell Biotech Co., Ltd., respectively. The hosts engaged the participants in a lively discussion on these topics and shared their insights and experiences.
目前，Drugverse的商標(biāo)持有者為大也醫(yī)藥信息咨詢(杭州)有限公司
Drugverse is a trademark owned by Daye Pharmaceutical Information Consulting (Hangzhou) Co., Ltd.
Drugverse創(chuàng)始團(tuán)隊及專家顧問團(tuán)成員具備15-35年國企、民企資深產(chǎn)業(yè)領(lǐng)域經(jīng)驗以及廣泛的國內(nèi)外人才、基金、項目、資源儲備。公司目前主要從事醫(yī)藥行業(yè)企業(yè)信息咨詢、戰(zhàn)略管理、成果轉(zhuǎn)化、創(chuàng)業(yè)輔導(dǎo)陪跑、投融資FA、政府招商引資等服務(wù)。
The founders and expert advisors of Drugverse have extensive industrial experience ranging from 15 to 35 years in both state-owned and private enterprises. They also have a rich network of domestic and foreign talents, funds, projects and resources. The company provides various services for the pharmaceutical industry, such as enterprise consulting、strategic management、 research commercialization、 entrepreneurial counseling、investment and financing FA、government investment promotion, etc.
微信公眾號請搜索：Drugverse
To follow us on WeChat, please search for: Drugverse